Abstract
Vascular damage triggers a combination of tightly integrated processes that may be subdivided into initiation of coagulation, propagation of thrombin formation, termination of the procoagulant reactions, elimination of the resulting clot, and tissue repair and regeneration [1, 2]. This collection of processes is subject to precise control, which localizes the response to the injured area, provides a level of response appropriate to the extent of injury, and maintains vascular hydraulic integrity until tissue repair is complete. The terms initiation, propagation, termination, elimination, and regeneration are useful to describe these discrete events, but all of these processes are highly intertwined and occur concomitantly (Fig. 1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jenny NS, Mann KG (1998) Coagulation cascade: an overview. In: Loscalzo J, Schafer AI (eds) Thrombosis and hemorrhage. Williams and Wilkins, Baltimore, pp 3–27
Mann KG (1992) Normal hemostasis. In: Kelley WN (ed) Textbook of internal medicine. Lippincott, Philadelphia, pp 1240–1245
Kalafatis M, Swords NA, Rand MD, Mann KG (1994) Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227:113–129
Lane DA, Olds RJ, Thein SL (2000) Antithrombin and its deficiency. In: Bloom AL, Forbes CD, Thomas DP et al (eds) Haemostasis and thrombosis. Churchill Livingstone, New York, pp 655–670
Olson ST, Bjork I, Shore JD (1993) Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 222:525–559
Broze GJ Jr (1987) Tissue-factor inhibitor is also a factor Xa inhibitor. Clin Res 35:597
Rosenberg RD, Rosenberg JS (1984) Natural anticoagulant mechanisms. J Clin Invest 74:1–6
Petersen TE, Dudek-Wojciechowska G, Sottrup-Jensen L et al (1979) Primary structure of antithrombin-III (heparin cofactor). In: Collen D, Wiman B, Verstrate M (eds) The physiological inhibitors of coagulation and fibrinolysis. Elsevier, Amsterdam, PP 43–54
Thaler E, Lechner K (1981) Antithrombin III deficiency and thromboembolism. Clin Haematol 10:369–390
Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA (1992) Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 116:754–761
Hathaway WE (1991) Clinical aspects of antithrombin III deficiency. Semin Hematol 28:19–23
Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr (1991) Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387–393
Rapaport SI (1991) The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66:6–15
Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71:335–343
Sandset PM, Sirnes PA, Abildgaard U (1989) Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 72:391–396
Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI (1991) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A 88:708–712
Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ Jr, Warren TG, Wun TC (1990) Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 76:1538–1545
Ellis V, Pyke C, Eriksen J, Solberg H, Dano K (1992) The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 667:13–31
Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW, Wilner GD, Vlodavsky I (1990) Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul 1:453–463
Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD (1986) Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci U S A 83:976–980
Singh JP, Chaikin MA, Stiles CD (1982) Phylogenetic analysis of platelet-derived growth factor by radio-receptor assay. J Cell Biol 95:667–671
Huang JS, Huang SS, Deuel TF (1983) Human platelet-derived growth factor: radioimmunoassay and discovery of a specific plasma-binding protein. J Cell Biol 97:383–388
Antoniades HN, Scher CD, Stiles CD (1979) Purification of human platelet-derived growth factor. Proc Natl Acad Sci USA 76:1809–1813
Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB (1983) Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258:7155–7160
Hsuan JJ (1989) Transforming growth factors beta. Br Med Bull 45:425–437
Oka Y, Orth DN (1983) Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest 72:249–259
Daniel TO, Gibbs VC, Milfay DF, Garovoy MR, Williams LT (1986) Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem 261:9579–9582
Nelsestuen GL, Shah AM, Harvey SB (2000) Vitamin K-dependent proteins. Vitam Horm 58:355–389
Furie B, Bouchard BA, Furie BC (1999) Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 93:1798–1808
Stenflo J (1999) Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Crit Rev Eukaryot Gene Expr 9:59–88
Magnusson S, Sottrup-Jensen L, Petersen TE, Morris HR, Dell A (1974) Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett 44:189–193
Stenflo J, Ferlund P, Egan W, Roepstorff P (1974) Vitamin K-dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 71:2730–2733
Stenflo J (1974) Vitamin K and the biosynthesis of prothrombin. IV Isolation of peptides containing prosthetic groups from normal prothrombin and the corresponding peptides from dicoumarol-induced prothrombin. J Biol Chem 249:5527–5535
Nelsestuen GL, Zytkovicz TH, Howard JB (1974) The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249:6347–6350
Scott DL, White SP, Browning JL, Rosa JJ, Gelb MH, Sigler PB (1991) Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science 254:1007–1010
McDonald JF, Evans TC Jr, Emeagwali DB, Hariharan M, Allewell NM, Pusey ML, Shah AM, Nelsestuen GL (1997) Ionic properties of membrane association by vitamin K-dependent proteins: the case for univalency. Biochemistry 36:15589–15598
Lu Y, Nelsestuen GL (1996) Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: implications for protein-membrane contact. Biochemistry 35:8193–8200
Christiansen WT, Jalbert LR, Robertson RM, Jhingan A, Prorok M, Castellino FJ (1995) Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid vesicles. Biochemistry 34:10376–10382
Seshadri TP, Skrzypczak-Jankun E, Yin M, Tulinsky A (1994) Differences in the metal ion structure between Sr- and Ca-prothrombin fragment 1. Biochemistry 33:1087–1092
Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B (1996) Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 271: 16227–16236
Zhang L, Castellino FJ (1994) The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the gamma-carboxyglutamic acid domain. J Biol Chem 269:3590–3595
Stenflo J, Stenberg Y, Muranyi A (2000) Calcium-binding EGF-like modules in coagulation proteinases: function of the calcium ion in module interactions. Biochim Biophys Acta 1477:51–63
McMullen BA, Fujikawa K, Kisiel W (1983) The occurrence of beta-hydroxyaspartic acid in the vitamin K-dependent blood coagulation zymogens. Biochem Biophys Res Commun 115:8–14
Stenflo J, Ohlin AK, Owen WG, Schneider WJ (1988) beta-Hydrox-yaspartic acid or beta-hydroxyasparagine in bovine low density lipoprotein receptor and in bovine thrombomodulin. J Biol Chem 263:21–24
Gronke RS, VanDusen WJ, Garsky VM, Jacobs JW, Sardana MK, Stern AM, Friedman PA (1989) Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc Natl Acad Sci U SA 86:3609–3613
Prendergast FG, Mann KG (1977) Differentiation of metal ion-induced transitions of prothrombin fragment 1. J Biol Chem 252:840–850
Soriano-Garcia M, Park CH, Tulinsky A, Ravichandran KG, Skrzypczak-Jankun E (1989) Structure of Ca2+ prothrombin fragment 1 including the conformation of the Gla domain. Biochemistry 28:6805–6810
Gardill SL, Suttie JW (1990) Vitamin K epoxide and quinone reductase activities. Evidence for reduction by a common enzyme. Biochem Pharmacol 40:1055–1061
Fasco MJ, Principe LM (1980) Vitamin K1 hydroquinone formation catalyzed by a microsomal reductase system. Biochem Biophys Res Commun 97:1487–1492
Furie B, Furie BC (1990) Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 75:1753–1762
Lollar P, Hill-Eubanks DC, Parker CG (1988) Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263:10451–10455
Cosgriff SW (1956) The effectiveness of an oral vitamin K in controlling excessive hypothrombinemia during anticoagulant therapy. Ann Intern Med 45:14–22
Hirsh J (1995) Optimal intensity and monitoring warfarin. Am J Cardiol 75:39B–426
Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 108:231S–246S
Lundblad RL, Kingdon HS, Mann KG (1976) Thrombin. Methods Enzymol 45:156–176
Kisiel W, Hanahan DJ (1973) Purification and characterization of human Factor II. Biochim Biophys Acta 304:103–113
Deguchi H, Takeya H, Gabazza EC, Nishioka J, Suzuki K (1997) Prothrombin kringle 1 domain interacts with factor Va during the assembly of prothrombinase complex. Biochem J 321:729–735
Sugo T, Nakamikawa C, Tanabe S, Matsuda M (1995) Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J Biochem (Tokyo) 117:244–250
Bajaj SP, Butkowski RJ, Mann KG (1975) Prothrombin fragments. Ca2+ binding and activation kinetics. J Biol Chem 250:2150–2156
Kotkow KJ, Deitcher SR, Furie B, Furie BC (1995) The second kringle domain of prothrombin promotes factor Va-mediated prothrombin activation by prothrombinase. J Biol Chem 270:4551–4557
Krishnaswamy S, Walker RK (1997) Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex. Biochemistry 36:3319–3330
Krishnaswamy S, Mann KG, Nesheim ME (1986) The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 261:8977–8984
Doyle MF, Mann KG (1990) Multiple active forms of thrombin. IV. Relative activities of meizothrombins. J Biol Chem 265:10693–10701
Myrmel KH, Lundblad RL, Mann KG (1976) Characteristics of the association between prothrombin fragment 2 and alpha-thrombin. Biochemistry 15:1767–1773
Nesheim ME, Abbott T, Jenny R, Mann KG (1988) Evidence that the thrombin-catalyzed feedback cleavage of fragment 1.2 at Arg154-Ser155 promotes the release of thrombin from the catalytic surface during the activation of bovine prothrombin. J Biol Chem 263: 1037–1044
Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ (1998) Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 95:7597–7602
Rouvier J, Braude R, Altman R (1975) Proceedings: fibrinogenolysis: studies on its degradation products. Thromb Diath Haemorrh 34:340
Roberts HR, Lefkowitz JB (1994) Inherited disorders of prothrombin conversion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principals and clinical practice. Lippincott, Philadelphia, pp 200–218
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703
Kisiel W, Davie EW (1975) Isolation and characterization of bovine factor VII. Biochemistry 14:4928–4934
Bajaj SP, Rapaport SI, Brown SF (1981) Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 256:253–259
Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U (1992) Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80:25–28
Radcliffe R, Nemerson Y (1975) Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 250:388–395
Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI (1979) Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 64:1056–1065
Lawson JH, Butenas S, Mann KG (1992) The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem 267:4834–4843
Kisiel W, Fujikawa K, Davie EW (1977) Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 16:4189–4194
Neuenschwander PF, Fiore MM, Morrissey JH (1993) Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 268:21489–21492
Lawson JH, Krishnaswamy S, Butenas S, Mann KG (1993) Extrinsic pathway proteolytic activity. Methods Enzymol 222:177–195
Pedersen AH, Lund-Hansen T, Komiyama Y, Petersen LC, Oester-gard PB, Kisiel W (1991) Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions. Thromb Haemost 65:528–534
Petersen LC, Olsen OH, Nielsen LS, Freskgard PO, Persson E (2000) Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor. Protein Sci 9:859–866
Lawson JH, Butenas S, Ribarik N, Mann KG (1993) Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 268:767–770
Briet E, Onvlee G (1987) Hip surgery in a patient with severe factor VII deficiency. Haemostasis 17:273–277
Mariani G, Mazzucconi MG, Hermans J, Ciavarella N, Faiella A, Hassan HJ, Mannucci PM, Nenci GG, Orlando M, Romoli D, Mandelli F (1981) Factor VII deficiency: immunological characterization of genetic variants and detection of carriers. Br J Haematol 48:7–14
Hall S, Rapaport SI, Amiral J (1964) A clinical and family study of hereditary proconvertin (factor VII) deficiency. Am J Med 37:172–181
Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H (1988) Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy (letter). Lancet 2:1193
Hedner U (1998) Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 9 [Suppl 1]:S147–S152
Thompson AR (1986) Structure, function, and molecular defects of factor IX. Blood 67:565–572
Fujikawa K, Davie EW (1976) Bovine factor IX (Christmas factor). Methods Enzymol 45:74–83
Jackson CM, Nemerson Y (1980) Blood coagulation. Annu Rev Biochem 49:765–811
Osterud B, Rapaport SI (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 74:5260–5264
Baglia FA, Sinha D, Walsh PN (1989) Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX. Blood 74:244–251
Kurachi K, Fujikawa K, Schmer G, Davie EW (1976) Inhibition of bovine factor IXa and factor Xab by antithrombin III. Biochemistry 15:373–377
Braunstein KM, Noyes CM, Griffith MJ, Lundblad RL, Roberts HR (1981) Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. J Clin Invest 68:1420–1426
Griffith MJ, Breitkreutz L, Trapp H, Briet E, Noyes CM, Lundblad RL, Roberts HR (1985) Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. J Clin Invest 75:4–10
Lawson JH, Mann KG (1991) Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 266:11317–11327
Biggs R, Douglas AS, MacFarlane RG (1952) Christmas disease: a condition previously mistaken for hemophilia. Br Med J 2:1384
Thompson AR, Chen SH (1993) Characterization of factor IX defects in hemophilia B patients. Methods Enzymol 222:143–169
Giannelli F, Green PM, Sommer SS, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG (1997) Haemophilia B: database of point mutations and short additions and deletions, 7th edn. Nucleic Acids Res 25:133–135
Reiner AP, Davie EW (1994) The physiology and biochemistry of factor IX. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG (eds) Haemostasis and thrombosis. Churchill Livingstone, New York, pp 309–331
Cherington V, Chiang GG, McGrath CA, Gaffney A, Galanopoulos T, Merrill W, Bizinkauskas CB, Hansen M, Sobolewski J, Levine PH, Greenberger JS, Hurwitz DR (1998) Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Hum Gene Ther 9:1397–1407
White SJ, Page SM, Margaritis P, Brownlee GG (1998) Long-term expression of human clotting factor IX from retrovirally transduced primary human keratinocytes in vivo. Hum Gene Ther 9:1187–1195
Di Scipio RG, Hermodson MA, Davie EW (1977) Activation of human factor X (Stuart factor) by a protease from Russell’s viper venom. Biochemistry 16:5253–5260
Davie EW, Fujikawa K, Kurachi K, Kisiel W (1979) The role of serine proteases in the blood coagulation cascade. Adv Enzymol Relat Areas Mol Biol 48:277–318
Osterud B, Rapaport SI (1970) Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX. Biochemistry 9:1854–1861
Jesty J, Silverberg SA (1979) Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 254:12337–12345
Kerbiriou DM, Griffin JH (1979) Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem 254:12020–12027
Girolami A, Coser P, Brunetti A, Prinoth O (1975) Classical factor X deficiency. Report of a further case. Acta Haematol 53:118–127
Egberg N, Heedman PA (1982) Simplified performance of amidolytic factor X assay. Thromb Res 25:437–440
Ewing NP, Kasper CK (1982) In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 77:749–752
Esmon CT (1984) Protein C. Prog Hemost Thromb 7:25–54
Stenflo J (1984) Structure and function of protein C. Semin Thromb Hemost 10:109–121
Kisiel W, Canfield WM (1981) Snake venom proteases that activate blood-coagulation factor V. Methods Enzymol 80:275–285
Kisiel W (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest 64:761–769
Lu D, Kalafatis M, Mann KG, Long GL (1996) Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 87:4708–4717
Dahlback B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90: 1004–1008
Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI (1984) Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 310: 559–562
Bertina RM (2000) Protein C deficiency and venous thrombosis—the search for the second genetic defect. Thromb Haemost 83:360–361
Hasstedt SJ, Bovill EG, Callas PW, Long GL (1998) An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 63:569–576
Lu D, Bovill EG, Long GL (1994) Molecular mechanism for familial protein C deficiency and thrombosis in protein C Vermont (Glu20 → Ala and Val34 → Met). J Biol Chem 269:29032–29038
Bovill EG, Hasstedt SJ, Leppert MF, Long GL (1999) Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost 82:662–666
Thompson AR (1994) Molecular genetics of hemostatic proteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, pp 55–80
Lu D, Kalafatis M, Mann KG, Long GL (1994) Loss of membrane-dependent factor Va cleavage: a mechanistic interpretation of the pathology of protein C Vermont. Blood 84:687–690
Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26:965–968
Maruyama I (1999) Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 82:718–721
Nelsestuen GL (1999) Enhancement of vitamin K-dependent protein function by modification of the gamma-carboxyglutamic acid domain: studies of protein C and factor VII. Trends Cardiovasc Med 9:162–167
Dahlback B (1983) Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 209:847–856
Lu D, Xie RL, Rydzewski A, Long GL (1997) The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Thromb Haemost 77:1156–1163
Di Scipio RG, Hermodson MA, Yates SG, Davie EW (1977) A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 16:698–706
Handford PA, Mayhew M, Baron M, Winship PR, Campbell ID, Brownlee GG (1991) Key residues involved in calcium-binding motifs in EGF-like domains. Nature 351:164–167
Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D (1995) The structure of a Ca(2+)-binding epidermal growth factorlike domain: its role in protein-protein interactions. Cell 82:131–141
Pauls JE, Hockin MF, Long GL, Mann KG (2000) Self-association of human protein S. Biochemistry 39:5468–5473
Walker FJ (1980) Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 255:5521–5524
Suzuki K, Nishioka J, Matsuda M, Murayama H, Hashimoto S (1984) Protein S is essential for the activated protein C-catalyzed inactivation of platelet-associated factor Va. J Biochem (Tokyo) 96:455–460
Walker FJ (1984) Protein S and the regulation of activated protein C. Semin Thromb Hemost 10:131–138
Solymoss S, Tucker MM, Tracy PB (1988) Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 263:14884–14890
Walker FJ, Chavin SI, Fay PJ (1987) Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys 252:322–328
Walker FJ (1984) Regulation of vitamin K-dependent protein S. Inactivation by thrombin. J Biol Chem 259:10335–10339
Koedam JA, Meijers JC, Sixma JJ, Bouma BN (1988) Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82:1236–1243
Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH (1994) Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 91:2728–2732
Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH (1993) Binding of protein S to factor Va associated with inhibition of prothrombi-nase that is independent of activated protein C. J Biol Chem 268: 2872–2877
Butenas S, van’t Veer C, Mann KG (1999) “Normal” thrombin generation. Blood 94:2169–2178
Mitchell CA, Kelemen SM, Salem HH (1988) The anticoagulant properties of a modified form of protein S. Thromb Haemost 60:298–304
Mahasandana C, Suvatte V, Chuansumrit A, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE (1990) Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 117:750–753
Comp PC, Nixon RR, Cooper MR, Esmon CT (1984) Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 74:2082–2088
Craig A, Taberner DA, Fisher AH, Foster DN, Mitra J (1990) Type I protein S deficiency and skin necrosis. Postgrad Med J 66:389–391
Chafa O, Fischer AM, Meriane F, Chellali F, Rahal S, Sternberg C, Benabadji M (1989) A new case of ‘type II’ inherited protein S deficiency. Br J Haematol 73:501–505
Broze GJ Jr, Miletich JP (1984) Human protein Z. J Clin Invest 73:933–938
Miletich JP, Broze GJ Jr (1987) Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy. Blood 69:1580–1586
Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K (1990) Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun 171:661–668
Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW (1990) Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun 172:1139–1144
Hogg PJ, Stenflo J (1991) Interaction of vitamin K-dependent protein Z with thrombin. Consequences for the amidolytic activity of thrombin and the interaction of thrombin with phospholipid vesicles. J Biol Chem 266:10953–10958
Hogg PJ, Stenflo J (1991) Interaction of human protein Z with thrombin: evaluation of the species difference in the interaction between bovine and human protein Z and thrombin. Biochem Biophys Res Commun 178:801–807
Han X, Fiehler R, Broze GJ Jr (1998) Isolation of a protein Z-de-pendent plasma protease inhibitor. Proc Natl Acad Sci USA 95: 9250–9255
Kemkes-Matthes B, Walmrath K, Matthes KJ (1995) Onkologie 18:195
Yin ZF, Huang ZF, Cui J, Fiehler R, Lasky N, Ginsburg D, Broze GJ Jr (2000) Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 97:6734–6738
Kemkes-Matthes B, Matthes KJ (1995) Protein Z deficiency: a new cause of bleeding tendency. Thromb Res 79:49–55
Kemkes-Matthes B, Mathes KJ, Sutor AH (1995) Protein Z bei Kindern mit Blutungsereignissen unklarer Genese. Erste klinische Daten. In: Scharrer I, Schramm W (eds) Hamophilie-Symposion Hamburg. Springer, Berlin Heidelberg New York, p 325
Kemkes-Matthes B, Matthes KJ (1995) Protein Z, a new haemostatic factor in liver diseases. Haemostasis 25:312–316
Greten J, Kreis I, Liliensiek B, Allenberg J, Amiral J, Ziegler R, Nawroth PP (1998) Localisation of protein Z in vascular lesions of patients with atherosclerosis. Vasa 27:144–148
Andrews BS, Rehemtulla A, Fowler BJ, Edgington TS, Mackman N (1991) Conservation of tissue factor primary sequence among three mammalian species. Gene 98:265–269
Mackman N, Fowler BJ, Edgington TS, Morrissey JH (1990) Functional analysis of the human tissue factor promoter and induction by serum. Proc Natl Acad Sci U S A 87:2254–2258
Mackman N (1995) Regulation of the tissue factor gene. FASEB J 9:883–889
Mackman N, Brand K, Edgington TS (1991) Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 174:1517–1526
Bach R, Konigsberg WH, Nemerson Y (1988) Human tissue factor contains thioester-linked palmitate and stearate on the cytoplasmic half-cystine. Biochemistry 27:4227–4231
Banner DW, D’Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380:41–46
Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr (1996) Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88:1583–1587
Huang ZF, Higuchi D, Lasky N, Broze GJ Jr (1997) Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90:944–951
Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P (1997) Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 390: 290–294
Stern DM, Nawroth PP, Kisiel W, Vehar G, Esmon CT (1985) The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X. J Biol Chem 260:6717–6722
Jackman RW, Beeler DL, VanDeWater L, Rosenberg RD (1986) Characterization of a thrombomodulin cDNA reveals structural similarity to the low-density lipoprotein receptor. Proc Natl Acad Sci USA 83:8834–8838
Jackman RW, Beeler DL, Fritze L, Soff G, Rosenberg RD (1987) Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci USA 84: 6425–6429
Wen DZ, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE (1987) Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry 26:4350–4357
Duda RJ Jr, O’Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL (1988) Concurrent assays of circulating bone G1a-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951–957
Tsiang M, Lentz SR, Sadler JE (1992) Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 267:6164–6170
Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S (1987) Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 6:1891–1897
Kurosawa S, Galvin JB, Esmon NL, Esmon CT (1987) Proteolytic formation and properties of functional domains of thrombomodulin. J Biol Chem 262:2206–2212
Nagashima M, Lundh E, Leonard JC, Morser J, Parkinson JF (1993) Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. J Biol Chem 268:2888–2892
Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386–391
Overduin M, de Beer T (2000) The plot thickens: how thrombin modulates blood clotting. Nat Struct Biol 7:267–269
Kane WH, Davie EW (1986) Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Natl Acad Sci U S A 83:6800–6804
Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG (1987) Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 84:4846–4850
Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312:342–347
Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN (1984) Structure of human factor VIII. Nature 312:337–342
Ortel TL, Takahashi N, Putnam FW (1984) Structural model of human ceruloplasmin based on internal triplication, hydrophilic/ hydrophobic character, and secondary structure of domains. Proc Natl Acad Sci U S A 81:4761–4765
Mann KG, Lawler CM, Vehar GA, Church WR (1984) Coagulation factor V contains copper ion. J Biol Chem 259:12949–12951
Bihoreau N, Pin S, de Kersabiec AM, Vidot F, Fontaine-Aupart MP (1993) Metal identification in human anti-hemophilia A factor (factor VIII). C R Acad Sci III 316:536–539
Stubbs JD, Lekutis C, Singer KL, Bui A, Yuzuki D, Srinivasan U, Parry G (1990) cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factorlike domains linked to factor VIII-like sequences. Proc Natl Acad Sci USA 87:8417–8421
Guinto ER, Esmon CT, Mann KG, MacGillivray RT (1992) The complete cDNA sequence of bovine coagulation factor V. J Biol Chem 267:2971–2978
Tracy PB, Eide LL, Bowie EJ, Mann KG (1982) Radioimmunoassay of factor V in human plasma and platelets. Blood 60:59–63
Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW (1984) Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line. J Clin Invest 73:654–658
Cerveny TJ, Fass DN, Mann KG (1984) Synthesis of coagulation factor V by cultured aortic endothelium. Blood 63:1467–1474
Kane WH, Majerus PW (1981) Purification and characterization of human coagulation factor V. J Biol Chem 256:1002–1007
Dahlback B (1980) Human coagulation factor V purification and thrombin-catalyzed activation. J Clin Invest 66:583–591
Kumar HPM, Besman MJ, Lundblad RL, Jenny NS, Mann KG (1999) Carbohydrate analysis of plasma factor V and factor VIII. Thromb Haemost Suppl (abstract) p 35
Hortin GL (1990) Sulfation of tyrosine residues in coagulation factor V. Blood 76:946–952
Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ (1994) Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 33:6952–6959
Xue J, Kalafatis M, Mann KG (1993) Determination of the disulfide bridges in factor Va light chain. Biochemistry 32:5917–5923
Xue J, Kalafatis M, Silveira JR, Kung C, Mann KG (1994) Determination of the disulfide bridges in factor Va heavy chain. Biochemistry 33:13109–13116
Pittman DD, Tomkinson KN, Kaufman RJ (1994) Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 269:17329–17337
Thorelli E, Kaufman RJ, Dahlback B (1998) The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 273:16140–16145
Nesheim ME, Foster WB, Hewick R, Mann KG (1984) Characterization of factor V activation intermediates. J Biol Chem 259:3187–3196
Suzuki K, Dahlback B, Stenflo J (1982) Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 257:6556–6564
Nesheim ME, Taswell JB, Mann KG (1979) The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 254:10952–10962
Mann KG, Jenny RJ, Krishnaswamy S (1988) Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 57:915–956
Kalafatis M, Rand MD, Jenny RJ, Ehrlich YH, Mann KG (1993) Phosphorylation of factor Va and factor Villa by activated platelets. Blood 81:704–719
Rand MD, Kalafatis M, Mann KG (1994) Platelet coagulation factor Va: the major secretory platelet phosphoprotein. Blood 83:2180–2190
Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactiva-tion of human factor V and human factor Va by activated protein C. J Biol Chem 269:31869–31880
Kalafatis M, Mann KG (1993) Role of the membrane in the inactiva-tion of factor Va by activated protein C. J Biol Chem 268:27246–27257
Mann KG, Hockin MF, Begin KJ, Kalafatis M (1997) Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 272:20678–20683
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67
Egan JO, Kalafatis M, Mann KG (1997) The effect of Arg306 → Ala and Arg506 → Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 6:2016–2027
Kalafatis M, Bertina RM, Rand MD, Mann KG (1995) Characterization of the molecular defect in factor VR506Q. J Biol Chem 270: 4053–4057
Kalafatis M, Lu D, Bertina RM, Long GL, Mann KG (1995) Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Arterioscler Thromb Vasc Biol 15:2181–2187
Zoller B, Hillarp A, Berntorp E, Dahlback B (1997) Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 48:45–58
Reitsma PH (1996) Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res 24:157–159
Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG (1995) Factor V New Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood 86:1820–1827
Vehar GA, Davie EW (1980) Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 19:401–410
Lollar P, Parker CG (1987) Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 262:17572–17576
Lollar P, Parker CG (1989) Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 28:666–674
Kane WH, Davie EW (1988) Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71:539–555
Michnick DA, Pittman DD, Wise RJ, Kaufman RJ (1994) Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 269:20095–20102
McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M (1995) Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Protein Sci 4:740–746
Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA (1991) Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266:740–746
Fay PJ, Haidaris PJ, Smudzin TM (1991) Human factor Villa sub-unit structure. Reconstruction of factor Villa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 266:8957–8962
Lollar P, Parker CG (1990) pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 265:1688–1692
Fay PJ, Smudzin TM (1992) Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor Villa. J Biol Chem 267:13246–13250
Lu D, Kalafatis M, Mann KG, Long GL (1996) Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 87:4708–4717
Fay PJ, Smudzin TM, Walker FJ (1991) Activated protein C-cat-alyzed inactivation of human factor VIII and factor Villa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 266:20139–20145
Hoyer LW (1987) Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol 18:153–161
Gitschier J (1991) The molecular basis of hemophilia A. Ann NY Acad Sci 614:89–96
Bouma BN, Griffin JH (1977) Human blood coagulation factor XL Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252:6432–6437
Hermodson M, Schmer G, Kurachi K (1977) Isolation, crystallization, and primary amino acid sequence of human platelet factor IV. J Biol Chem 252:6276–6279
Thompson RE, Mandle R Jr, Kaplan AP (1977) Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 60:1376–1380
Walsh PN, Baglia FA, Jameson BA (1993) Factor XI: structurefunction relationships utilizing monoclonal antibodies protein modification, computational chemistry, and rational synthetic peptide design. Methods Enzymol 222:65–96
McMullen BA, Fujikawa K, Davie EW (1991) Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 30:2056–2060
Walsh PN, Griffin JH (1981) Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 57:106–118
Walsh PN (1972) The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Br J Haematol 22:393–405
Schiffman S, Yeh CH (1990) Purification and characterization of platelet factor XL. Thromb Res 60:87–97
Walsh PN, Biggs R (1972) The role of platelets in intrinsic factor-Xa formation. Br J Haematol 22:743–760
Walsh PN (1972) The role of platelets in the contact phase of blood coagulation. Br J Haematol 22:237–254
Bouma BN, Griffin JH (1977) Human blood coagulation factor XL Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252:6432–6437
Rosenthal RH, Dreskin OH, Rosenthal N (1955) Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood 10:120
Forbes CD, Ratnoff OD (1972) Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum. J Lab Clin Med 79:113–127
Seligsohn U (1993) Factor XI deficiency. Thromb Haemost 70:68–71
Rapaport SI, Proctor RR, Patch MJ (1961) The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 18:149–155
Leiba H, Ramot B, Many A (1965) Heredity and coagulation studies in ten families with Factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol 11:654–665
Seligsohn U (1978) High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 51:1223–1228
Shpilberg 0, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, Stern C, Weiss E, Seligsohn U (1995) One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 85:429–432
Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB (1988) Inheritance and bleeding in factor XI deficiency. Br J Haematol 69:521–528
Asakai R, Chung DW, Ratnoff OD, Davie EW (1989) Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A 86:7667–7671
Meijers JC, Davie EW, Chung DW (1992) Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood 79:1435–1440
Schmaier AH (1994) Contact activation. In: Loscalzo J, Schafer AI (eds) Thrombosis and hemorrhage. Williams and Wilkins, Baltimore, pp 105–127
Griffin JH, Cochrane CG (1976) Human factor XII (Hageman factor). Methods Enzymol 45:56–65
Saito H, Ratnoff OD, Pensky J (1976) Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 88:506–514
McMullen BA, Fujikawa K (1985) Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem 260:5328–5341
Gordon EM, Douglas JG, Ratnoff OD, Arafah BM (1985) The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. Blood 66:602–605
Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L (1988) Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 111:52–56
Gordon EM, Johnson TR, Ramos LP, Schmeidler-Sapiro KT (1991) Enhanced expression of factor XII (Hageman factor) in isolated livers of estrogen- and prolactin-treated rats. J Lab Clin Med 117: 353–358
Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S (1985) Structural organization of the human kinino-gen gene and a model for its evolution. J Biol Chem 260:8610–8617
Kellermann J, Lottspeich F, Henschen A, Muller-Esterl W (1986) Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. Eur J Biochem 154:471–478
Proud D, Pierce JV, Pisano JJ (1980) Radioimmunoassay of human high-molecular-weight kininogen in normal and deficient plasmas. J Lab Clin Med 95:563–574
Wuepper KD, Miller DR, Lacombe MJ (1975) Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 56:1663–1672
Cheung PP, Kunapuli SP, Scott CF, Wachtfogel YT, Colman RW (1993) Genetic basis of total kininogen deficiency in Williams’trait. J Biol Chem 268:23361–23365
Fisher CA, Schmaier AH, Addonizio VP, Colman RW (1982) Assay of prekallikrein in human plasma: comparison of amidolytic, estero-lytic, coagulation, and immunochemical assays. Blood 59:963–970
Mandle RJ, Colman RW, Kaplan AP (1976) Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A 73:4179–4183
Castaman G, Ruggeri M, Rodeghiero F (1990) A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members. Ric Clin Lab 20:239–244
McDonagh J, McDonagh RP Jr, Delage JM, Wagner RH (1969) Factor XIII in human plasma and platelets. J Clin Invest 48:940–946
Henriksson P, Becker S, Lynch G, McDonagh J (1985) Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest 76:528–534
Muszbek L, Adany R, Szegedi G, Polgar J, Kavai M (1985) Factor XIII of blood coagulation in human monocytes. Thromb Res 37:401–410
Takagi T, Doolittle RF (1974) Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 13:750–756
Lorand L, Jeong JM, Radek JT, Wilson J (1993) Human plasma factor XIII: subunit interactions and activation of zymogen. Methods Enzymol 222:22–35
McDonagh J (1994) Structure and function of factor XIII. In: Colman RW, Hirsh J, Marder VJ, Sandberg H (eds) Hemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, pp 301–313
Ichinose A, Kaetsu H (1993) Molecular approach to structure-function relationship of human coagulation factor XIII. Methods Enzymol 222:36–51
Mikuni Y, Iwanaga S, Konishi K (1973) A peptide released from plasma fibrin stabilizing factor in the conversion to the active enzyme by thrombin. Biochem Biophys Res Commun 54:1393–1403
Procyk R, Blomback B (1988) Factor XIII-induced cross-linking in solutions of fibrinogen and fibronectin. Biochim Biophys Acta 967:304–313
Procyk R, Adamson L, Block M, Blomback B (1985) Factor XIII catalyzed formation of fibrinogen-fibronectin oligomers — a thiol-enhanced process. Thromb Res 40:833–852
Tamaki T, Aoki N (1982) Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 257:14767–14772
Chen R, Doolittle RF (1971) Cross-linking sites in human and bovine fibrin. Biochemistry 10:4487–4491
Kanaide H, Shainoff JR (1975) Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIa). J Lab Clin Med 85:574–597
Mosher DF (1984) Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem 58:63–68
Mosher DF, Schad PE (1979) Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. J Clin Invest 64:781–787
Mui PT, Ganguly P (1977) Cross-linking of actin and fibrin by fibrin-stabilizing factor. Am J Physiol 233:H346–H349
Lynch GW, Slayter HS, Miller BE, McDonagh J (1987) Characterization of thrombospondin as a substrate for factor XIII transglutaminase. J Biol Chem 262:1772–1778
Mikkola H, Syrjala M, Rasi V, Vahtera E, Hamalainen E, Peltonen L, Palotie A (1994) Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 84:517–525
Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ (1998) Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 79:8–13
Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A (1999) Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 142:295–300
Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ (1999) Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 93:906–908
Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH, Araujo AG, Piccinato CE, Zago MA (1999) Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 81:676–679
Elbaz A, Poirier 0, Canaple S, Chedru F, Cambien F, Amarenco P (2000) The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 95:586–591
Renner W, Koppel H, Hoffmann C, Schallmoser K, Stanger O, Toplak H, Wascher TC, Pilger E (2000) Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu. Common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 99:35–39
Kohler HP, Ariens RA, Whitaker P, Grant PJ (1998) A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity (letter). Thromb Haemost 80:704
Kangsadalampai S, Board PG (1998) The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 92:2766–2770
Anwar R, Gallivan L, Edmonds SD, Markham AF (1999) Geno-type/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII-specific activity. Blood 93:897–905
Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ (2000) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96:988–995
Shafer JA (1988) CRC critical reviews. Clin Lab Sci 26:1–4
Doolittle RF (1984) Fibrinogen and fibrin. Annu Rev Biochem 53:195–229
Blomback B, Blomback M, Edman P, Hessel B (1966) Human fibrinopeptides. Isolation, characterization and structure. Biochim Biophys Acta 115:371–396
Mosesson MW (1992) The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 29:177–188
Blomback B, Hessel B, Hogg D (1976) Disulfide bridges in NH2-terminal part of human fibrinogen. Thromb Res 8:639–658
Blomback B, Blomback M, Hessel B, Iwanaga S (1967) Structure of N-terminal fragments of fibrinogen and specificity of thrombin. Nature 215:1445–1448
Henschen A, Lottspeich F, Kehl M, Southan C (1983) Covalent structure of fibrinogen. Ann N Y Acad Sci 408:28–43
Doolittle RF, Goldbaum DM, Doolittle LR (1978) Designation of sequences involved in the “coiled-coil” interdomainal connections in fibrinogen: constructions of an atomic scale model. J Mol Biol 120:311–325
Henschen A (1964) Number and reactivity of disulfide bonds in fibrinogen and fibrin. Arkiv Kemi 22:355–359
Bouma H, Takagi T, Doolittle RF (1978) The arrangement of disulfide bonds in fragment D from human fibrinogen. Thromb Res 13: 557–562
Hardy JJ, Carrell NA, McDonagh J (1983) Calcium ion functions in fibrinogen conversion to fibrin. Ann N Y Acad Sci 408:279–287
Dang CV, Ebert RF, Bell WR (1985) Localization of a fibrinogen calcium binding site between gamma-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 260:9713–9719
Nieuwenhuizen W, Haverkate F (1983) Calcium-binding regions in fibrinogen. Ann N Y Acad Sci 408:92–96
Spraggon G, Everse SJ, Doolittle RF (1997) Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 389:455–462
Everse SJ, Spraggon G, Veerapandian L, Doolittle RF (1999) Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Proamide. Biochemistry 38:2941–2946
Doolittle RF, Spraggon G, Everse SJ (1999) Crystal structures of fragments D and double-D from fibrinogen and fibrin. Thromb Haemost 82:271–276
Ridgway HJ, Brennan SO, Loreth RM, George PM (1997) Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization. Br J Haematol 99:562–569
Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST (1992) Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461–610 (Lys 461 AAA → stop TAA). Blood 80:1972–1979
Furlan M, Steinmann C, Jungo M, Bogli C, Baudo F, Redaelli R, Fedeli F, Lammle B (1994) A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III. J Biol Chem 269:33129–33134
Mammen EF (1983) Seminars in thrombosis and hemostasis. Semin Thromb Hemost 9:1–72
Neerman-Arbez M, de Moerloose P, Bridel C, Honsberger A, Schonborner A, Rossier C, Peerlinck K, Claeyssens S, Di Michèle D, d’Oiron R, Dreyfus M, Laubriat-Bianchin M, Dieval J, Antonarakis SE, Morris MA (2000) Mutations in the fibrinogen A alpha gene account for the majority of cases of congenital afibrinogenemia. Blood 96:149–152
Fellowes AP, Brennan SO, Holme R, Stormorken H, Brosstad FR, George PM (2000) Homozygous truncation of the fibrinogen A alpha chain within the coiled coil causes congenital afibrinogenemia. Blood 96:773–775
Everse SJ, Spraggon G, Doolittle RF (1998) A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 80:1–9
Cote HC, Lord ST, Pratt KP (1998) Gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. Blood 92:2195–2212
Fellowes AP, Brennan SO, Ridgway HJ, Heaton DC, George PM (1998) Electrospray ionization mass spectrometry identification of fibrinogen Banks Peninsula (gamma280Ty → Cys): a new variant with defective polymerization. Br J Haematol 101:24–31
Lounes KC, Soria C, Valognes A, Turchini MF, Soria J, Koopman J (1999) Fibrinogen Bastia (gamma 318 Asp → Tyr): a novel abnormal fibrinogen characterized by defective fibrin polymerization. Thromb Haemost 82:1639–1643
Dempfle CE, Henschen A (1990) Fibrinogen Mannheim I-identification of an A alpha19 Arg to Gly substitution in dysfibrinogenemia associated with bleeding tendency. In: Matsuda M, Iwanaga S, Takada A, Henschen A (eds) Fibrinogen, current basic and clinical aspects. Elsevier Science, Amsterdam, pp 159–166
Kudryk B, Blomback B, Blomback M (1976) Fibrinogen Detroit — an abnormal fibrinogen with non-functional NH2-terminal polymerization domain. Thromb Res 9:25–36
Budzynski AZ, Marder VJ, Menache D, Guillin MC (1974) Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen (Paris I). Nature 252:66–68
Finlayson JS, Reamer LA, Mosesson MW, Menache D (1980) Fibrinopeptide release from fibrinogen Paris I. Thromb Res 17:577–579
Mosesson MW, Amrani DL, Menache D (1976) Studies on the structural abnormality of fibrinogen Paris I. J Clin Invest 57:782–790
Rosenberg JB, Newman PJ, Mosesson MW, Guillin MC, Amrani DL (1993) Paris I dysfibrinogenemia: a point mutation in intron 8 results in insertion of a 15-amino acid sequence in the fibrinogen gamma-chain. Thromb Haemost 69:217–220
Mosesson MW, Finlayson JS, Umfleet RA (1972) Human fibrinogen heterogeneities. 3. Identification of chain variants. J Biol Chem 247: 5223–5227
Lawrence SO, Wright TW, Francis CW, Fay PJ, Haidaris PJ (1993) Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. Blood 82:2406–2413
Peerschke EI, Francis CW, Marder VJ (1986) Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood 67:385–390
Wolfenstein-Todel C, Mosesson MW (1980) Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma’). Proc Natl Acad Sci USA 77:5069–5073
Francis CW, Marder VJ, Martin SE (1980) Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem 255:5599–5604
Siebenlist KR, Meh DA, Mosesson MW (1996) Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry 35:10448–10453
Falls LA, Farrell DH (1997) Resistance of gamma A/gamma’ fibrin clots to fibrinolysis. J Biol Chem 272:14251–14256
Moaddel M, Farrell DH, Daugherty MA, Fried MG (2000) Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma’ peptide. Biochemistry 39:6698–6705
Reeve EG, Franks JJ (1974) Fibrinogen synthesis, distribution and degradation. Semin Thromb Hemost 1:129
Fuller GM, Otto JM, Woloski BM, McGary CT, Adams MA (1985) The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J Cell Biol 101:1481–1486
Huber P, Laurent M, Dalmon J (1990) Human beta-fibrinogen gene expression. Upstream sequences involved in its tissue-specific expression and its dexamethasone and interleukin-6 stimulation. J Biol Chem 265:5695–5701
Cook NS, Ubben D (1990) Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 11:444–451
Ernst E, Resch KL (1995) Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 16 [Suppl A]:47–52
Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL (1995) Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9:2020–2033
Broze GJ Jr (1995) Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46:103–112
Broze GJ Jr, Lange GW, Duffin KL, MacPhail L (1994) Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5:551–559
Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr (1989) Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832–18837
Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP (1990) Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 87: 8869–8873
Broze GJ Jr (1995) Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 6 [Suppl 1]: S7–S13
Lindhout T, Willems G, Blezer R, Hemker HC (1994) Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem J 297:131–136
Huang ZF, Wun TC, Broze GJ Jr (1993) Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 268:26950–26955
Huang ZF, Broze G Jr (1997) Consequences of tissue factor pathway inhibitor gene-disruption in mice. Thromb Haemost 78:699–704
Jesty J (1978) The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 185:165–173
Olson ST, Shore JD (1982) Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257: 14891–14895
Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P (1981) The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13 C nuclear-magnetic-resonance studies. Biochem J 197:599–609
Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA (1989) Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 87: 53S-60S
von Blohn G, Hellstern P, Köhler M, Scheffler P, Wenzel E (1986) Clinical aspects of acquired antithrombin III deficiency. Behring Inst Mitt 79:200–215
Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S (1990) Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76:1–16
Krishnaswamy S, Jones KC, Mann KG (1988) Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 263:3823–3834
Krishnaswamy S, Mann KG (1988) The binding of factor Va to phospholipid vesicles. J Biol Chem 263:5714–5723
Krishnaswamy S (1990) Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation. J Biol Chem 265:3708–3718
Tracy PB, Nesheim ME, Mann KG (1981) Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 256:743–751
Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG (1992) Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 267:26110–26120
Mann KG (1976) Prothrombin. Methods Enzymol 45:123–156
Kalafatis M, Xue J, Lawler CM, Mann KG (1994) Contribution of the heavy and light chains of factor Va to the interaction with factor Xa. Biochemistry 33:6538–6545
Walker RK, Krishnaswamy S (1993) The influence of factor Va on the active site of factor Xa. J Biol Chem 268:13920–13929
Warner ED, Brinkhous KM, Smith HP (1936) A quantitative study of blood clotting. Am J Physiol 114:667–675
Quick AJ (1999) On the constitution of prothrombin. Am J Physiol 140:212–220
Langdell RD, Wagner RH, Brinkhous KMW (1953) Effect of antihemophilic factor on one-stage clotting tests: a presumptive test of hemophilia and a single one-stage anti-hemophilic factor assay procedure. J Lab Clin Med 41:7637–7647
Nemerson Y (1988) Tissue factor and hemostasis. Blood 71:1–8
Butenas S, Mann KG (1996) Kinetics of human factor VII activation. Biochemistry 35:1904–1910
Morrison SA, Jesty J (1984) Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 63:1338–1347
Krishnaswamy S (1992) The interaction of human factor VIIa with tissue factor. J Biol Chem 267:23696–23706
Silverberg SA, Nemerson Y, Zur M (1977) Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. J Biol Chem 252:8481–8488
Patek AJ, Taylor F (1937) Hemophilia II: some properties of a substance obtained from normal plasma effective in accelerating the clotting of hemophilic blood. J Clin Invest 16:113–124
Brinkhous KM (1947) Clotting defect in hemophilia: deficiency in a plasma factor required for platelet utilization. Proc Soc Exp Bio Med 66:117–120
Aggeler PM, White SG, Glendenning MB (1952) Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc Soc Exp Bio Med 79:692–694
Schulman II (1952) Hemorrhagic disease in an infant due to deficiency of a previously undescribed clotting factor. Blood 7:794–807
Tefler TP, Denson KW, Wright DR (1956) A “new” coagulation defect. Br J Haematol 2:308–312
Owren PA, Cooper T (1955) Parahemophilia. Arch Intern Med 95:194–201
Roberts HR, Foster PA (1987) Inherited disorders of prothrombin conversion. Lippincott, Philadelphia, pp 162–181
Wiggins RC, Cochrane CC (1979) The autoactivation of rabbit Hageman factor. J Exp Med 150:1122–1133
Silverberg M, Dunn JT, Garen L, Kaplan AP (1980) Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 255:7281–7286
Scott CF, Silver LD, Schapira M, Colman RW (1984) Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a proco-factor. J Clin Invest 73:954–962
Scott CF, Silver LD, Purdon AD, Colman RW (1985) Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 260:10856–10863
Ratnoff OD, Coply JE (1955) A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34:602–613
Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP (1975) Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56:1650–1662
Saito H, Ratnoff OD, Waldmann R (1975) Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface medicated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular per-meability(PF/DIL). J Clin Invest 55:1082–1089
Schmaier AH (1998) Plasma contact activation: a revised hypothesis. Biol Res 31:251–262
Rojkjaer R, Hasan AA, Motta G, Schousboe I, Schmaier AH (1998) Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 80:74–81
Gailani D, Broze GJ Jr (1991) Factor XI activation in a revised model of blood coagulation. Science 253:909–912
Heldebrant CM, Butkowski RJ, Bajaj SP, Mann KG (1973) The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation. J Biol Chem 248:7149–7163
Heldebrant CM, Mann KG (1973) The activation of prothrombin. I. Isolation and preliminary characterization of intermediates. J Biol Chem 248:3642–3652
Heldebrant CM, Noyes C, Kingdon HS, Mann KG (1973) The activation of prothrombin. III. The partial amino acid sequences at the amino terminal of prothrombin and the intermediates of activation. Biochem Biophys Res Commun 54:155–160
Mann KG, Bajaj SP, Heldebrant CM, Butkowski RJ, Fass DN (1973) Intermediates of prothrombin activation. Ser Haematol 6:479–493
Malhotra OP, Nesheim ME, Mann KG (1985) The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. J Biol Chem 260:279–287
Ryan US (1995) Endothelial cells. In: Barker JH, Anderson GL, Menger MD (eds) Critically applied microcirculation research. CRC Press, Boca Raton, FL, pp 407–418
Griendling KK, Alexander RW (1996) Endothelial control of the cardiovascular system: recent advances. FASEB J 10:283–292
Rodgers GM (1999) Endothelium and the regulation of hemostasis. In: Lee GR, Lickens J, Paraskevas F, Green JP, Rodgers GM, Foersten J (eds) Wintrobe’s clinical hematology. Williams and Wilkins, Baltimore, pp 765–773
Colman RW, Marder VJ, Salzman EW, Hirsh J (1994) Overview of hemostasis. In: Colman RW, Hirsh J, Marden VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, pp 3–18
Makrides SC, Ryan US (1998) Overview of the endothelium. In: Schafer AI, Loscalzo J (eds) Thrombosis and hemorrhage, Williams and Wilkens, Baltimore, pp 295–306
Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743–4746
Esmon CT (1987) The regulation of natural anticoagulant pathways. Science 235:1348–1352
Fair DS, Marlar RA, Levin EG (1986) Human endothelial cells synthesize protein S. Blood 67:1168–1171
More L, Sim R, Hudson M, Dhillon AP, Pounder R, Wakefield AJ (1993) Immunohistochemical study of tissue factor expression in normal intestine and idiopathic inflammatory bowel disease. J Clin Pathol 46:703–708
Liu L, Rodgers GM (1996) Characterization of an inducible endothelial cell prothrombin activator. Blood 88:2989–2994
Broze GJ Jr (1995) Tissue factor pathway inhibitor. Thromb Haemost 74:90–93
Stern D, Nawroth P, Handley D, Kisiel W (1985) An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 82: 2523–2527
Shuman MA (1986) Thrombin-cellular interactions. Ann NY Acad Sci 485:228–239
Lindahl U, Backstrom G, Thunberg L, Leder IG (1980) Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombinbinding sequence of heparin. Proc Natl Acad Sci USA 77:6551–6555
Marcum JA, Rosenberg RD (1984) Anticoagulantly active heparinlike molecules from vascular tissue. Biochemistry 23:1730–1737
Tollefsen DM, Pestka CA (1985) Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 66:769–774
Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D (1992) Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 80:966–974
Philips M, Juul AG, Thorsen S (1984) Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 802:99–110
Lee MH, Vosburgh E, Anderson K, McDonagh J (1993) Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 81:2357–2362
Schleef RR, Higgins DL, Pillemer E, Levitt LJ (1989) Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 83:1747–1752
Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D (1992) Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729–1733
Nilsson IM, Ljungner H, Tengborn L (1985) Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res) 290:1453–1456
Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3–9
Paramo JA, Colucci M, Collen D (1985) Plasminogen activation inhibitor in the blood of particles with coronary artery disease. Br Med J 291:573–574
Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457–462
Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 89:6998–7002
Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK (1993) Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13:1090–1100
Palmer RM, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664–666
Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley, K.A. Gayle RB,Maliszewski CR (1997) The endothelial cell ecto-AD-Pase responsible for inhibition of platelet function is CD39. J Clin Invest 99:1351–1360
Moncada S (1982) Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol 76:3–31
Body SC (1996) Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 27 [Suppl 1]:S13–S25
Mann KG, van’t Veer C, Cawthern K, Butenas S (1998) The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis 9 [Suppl 1]:S3–S7
Bombeli T, Karsan A, Tait JF, Harlan JM (1997) Apoptotic vascular endothelial cells become procoagulant. Blood 89:2429–2442
Levin EG, Santell L, Osborn KG (1997) The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J Cell Sci 110:139–148
Grant PJ, Medcalf RL (1990) Hormonal regulation of haemostasis and the molecular biology of the fibrinolytic system. Clin Sci (Colch) 78:3–11
Hajjar KA, Hamel NM, Harpel PC, Nachman RL (1987) Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 80:1712–1719
Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114–3124
Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919
Bachmann F, Kruithof IE (1984) Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 10:6–17
Blasi F, Vassalli JD, Dano K (1987) Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104:801–804
Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139–266
Blasi F (1988) Surface receptors for urokinase plasminogen activation. Fibrinolysis 2:73
Rodgers GM, Shuman MA (1985) Characterization of the interaction between factor Xa and bovine aortic endothelial cells. Biochim Biophys Acta 844:320–329
Charo IF, Shak S, Karasek MA, Davison PM, Goldstein IM (1984) Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest 74:914–919
Speiser W, Anders E, Preissner KT, Wagner O, Muller-Berghaus G (1987) Differences in coagulant and fibrinolytic activities of cultured human endothelial cells derived from omental tissue micro-vessels and umbilical veins. Blood 69:964–967
Rodgers GM (1988) Hemostatic properties of normal and perturbed vascular cells. FASEB J 2:116–123
Celi A, Lorenzet R, Furie B, Furie BC (1997) Platelet-leukocyte-en-dothelial cell interaction on the blood vessel wall. Semin Hematol 34:327–335
Lasky LA (1992) Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258:964–969
Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314
Tedder TF, Steeber DA, Chen A, Engel P (1995) The selectins: vascular adhesion molecules. FASEB J 9:866–873
Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60–66
McEver RP (1998) Interactions of leukocytes with the vessel wall. In: Loscalzo J, Schafer AI (eds) Thrombosis and hemorrhage. Williams and Wilkens, Baltimore, pp 321–336
Bargatze RF, Kurk S, Butcher EC, Jutila MA (1994) Neutrophils roll on adherent neutrophils bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. J Exp Med 180:1785–1792
Tracy PB, Eide LL, Mann KG (1985) Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 260:2119–2124
Tracy PB, Rohrbach MS, Mann KG (1983) Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258:7264–7267
Thiagarajan P, Niemetz J (1980) Procoagulant-tissue factor activity of circulating peripheral blood leukocytes. Results of in vivo studies. Thromb Res 17:891–896
Miller CL, Graziano C, Lim RC, Chin M (1981) Generation of tissue factor by patient monocytes: correlation to thromboembolic complications. Thromb Haemost 46:489–495
Osterud B, Due J Jr (1984) Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. Scand J Haematol 32:258–264
Blakowski SA, Zacharski LR, Beck JR (1986) Postoperative elevation of human peripheral blood monocyte tissue factor coagulant activity. J Lab Clin Med 108:117–120
Crawford N, Scrutton MC (1994) Biochemistry of the blood platelet. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG (eds) Hemostasis and thrombosis. Churchill Livingstone, New York, pp 89–114
Tuszynski GP, Bevacqua SJ, Schmaier AH, Colman RW, Walsh PN (1982) Factor XI antigen and activity in human platelets. Blood 59:1148–1156
Niewiarowski S, Thomas DP (1969) Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 222:1269–1270
Levine SP, Wohl H (1976) Human platelet factor IV: purification and characterization by affinity chromatography. Purification of human platelet factor IV. J Biol Chem 251:324–328
Lawler JW, Slayter HS, Coligan JE (1978) Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 253:8609–8616
Koutts J, Walsh PN, Plow EF, Fenton JW, Bouma BN, Zimmerman TS (1978) Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest 62: 1255–1263
Keenan JP, Solum NO (1972) Quantitative studies on the release of platelet fibrinogen by thrombin. Br J Haematol 23:461–466
Zucker MB, Mosesson MW, Broekman MJ, Kaplan KL (1979) Release of platelet fibronectin (cold-insoluble globulin) from alpha granules induced by thrombin or collagen; lack of requirement for plasma fibronectin in ADP-induced platelet aggregation. Blood 54:8–12
Viskup RW, Tracy PB, Mann KG (1987) The isolation of human platelet factor V. Blood 69:1188–1195
Schmaier AH, Zuckerberg A, Silverman C, Kuchibhotla J, Tuszynski GP, Colman RW (1983) High-molecular-weight kinino-gen. A secreted platelet protein. J Clin Invest 71:1477–1489
Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B (1989) PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59:305–312
Hamburger SA, McEver RP (1990) GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 75:550–554
Cronlund AL, Walsh PN (1992) A low-molecular-weight platelet inhibitor of factor XIa: purification, characterization, and possible role in blood coagulation. Biochemistry 31:1685–1694
Bagdasarian A, Colman RW (1978) Subcellular localization and purification of platelet alpha1-antitrypsin. Blood 51:139–156
Schwarz HP, Heeb MJ, Wencel-Drake JD, Griffin JH (1985) Identification and quantitation of protein S in human platelets. Blood 66:1452–1455
Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr (1988) Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 72:2020–2025
Plow EF, Collen D (1981) The presence and release of alpha 2-anti-plasmin from human platelets. Blood 58:1069–1074
Holt JC, Niewiarowski S (1980) Secretion of plasminogen by washed human platelets. Circulation 62:342
Erickson LA, Hekman CM, Loskutoff DJ (1985) The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82:8710–8714
Kruithof EK, Tran-Thang C, Bachmann F (1986) Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 55:201–205
Antoniades HN (1981) Human platelet-derived growth factor (PDGF): purification of PDGF-I and PDGF-II and separation of their reduced subunits. Proc Natl Acad Sci USA 78:7314–7317
Heldin CH, Westermark B, Wasteson A (1981) Platelet-derived growth factor. Isolation by a large-scale procedure and analysis of subunit composition. Biochem J 193:907–913
Deuel TF, Huang JS, Proffitt RT, Baenziger JU, Chang D, Kennedy BB (1981) Human platelet-derived growth factor. Purification and resolution into two active protein fractions. J Biol Chem 256:8896–8899
Raines EW, Ross R (1982) Platelet-derived growth factor. I. High-yield purification and evidence for multiple forms. J Biol Chem 257:5154–5160
Childs CB, Proper JA, Tucker RF, Moses HL (1982) Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 79:5312–5316
Clemmons DR, Isley WL, Brown MT (1983) Dialyzable factor in human serum of platelet origin stimulates endothelial cell replication and growth. Proc Natl Acad Sci USA 80:1641–1645
King GL, Buchwald S (1984) Characterization and partial purification of an endothelial cell growth factor from human platelets. J Clin Invest 73:392–396
Harrison P, Cramer EM (1993) Platelet alpha-granules. Blood Rev 7:52–62
Chesney CM, Harper E, Colman RW (1974) Human platelet collagenase. J Clin Invest 53:1647–1654
Legrand Y, Caen JP, Robert L, Wautier JL (1977) Platelet elastase and leukocyte elastase are two different entities. Thromb Haemost 37:580–582
McNicol A, Israels SJ (1999) Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 95:1–18
White JG (1987) Views of the platelet cytoskeleton at rest and at work. Ann N Y Acad Sci 509:156–176
Hartwig JH (1998) Platelet morphology. In: Lescalzo J, Schafer AI (eds) Thrombosis and hemorrhage. Williams and Wilkins, Baltimore, pp 207–228
Parise LV, Boudignon-Proudhon C, Keely PJ, Niak UP (1999) Platelets in hemostasis and thrombosis. In: Foersten J, Lukens J, Paraskevas F, Green JP, Rodgers GM (eds) Wintrobe’s clinical hematology. Williams and Wilkens, Baltimore, pp 661–683
Kansas GS (1996) Selectins and their ligands: current concepts and controversies. Blood 88:3259–3287
Nurden AT (1994) Human platelet membrane glycoproteins. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG (eds) Hemostasis and thrombosis. Churchill Livingstone, New York, pp 115–165
Bevers EM, Comfurius P, Zwaal RF (1983) Changes in membrane phospholipid distribution during platelet activation. Biochim Bio-phys Acta 736:57–66
Bennett, JS, Vilaire, G (1979) Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 64:1393–1401
Plow EF, McEver RP, Coller BS, Woods VL Jr, Marguerie GA, Ginsberg MH (1985) Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 66:724–727
Plow EF, Ginsberg MH (1981) Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 256:9477–9482
Weiss HJ, Tschopp TB, Baumgartner HR, Sussman II, Johnson MM, Egan JJ (1974) Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med 57:920–925
Hagen I, Nurden A, Bjerrum OJ, Solum NO, Caen J (1980) Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. J Clin Invest 65:722–731
Tobelem G, Levy-Toledano S, Nurden AT, Degos L, Caen JP, Malmsten C, Kindahl H (1979) Further studies on a specific platelet antibody found in Bernard-Soulier syndrome and its effects on normal platelet function. Br J Haematol 41:427–436
Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM (1986) The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 261:12579–12585
Michelson AD (1992) Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. Semin Thromb Hemost 18:18–27
Michelson AD, Barnard MR (1987) Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood 70:1673–1678
George JN, Torres MM (1988) Thrombin decreases von Willebrand factor binding to platelet glycoprotein Ib. Blood 71:1253–1259
Hourdille P, Heilmann E, Combrie R, Winckler J, Clemetson KJ, Nurden AT (1990) Thrombin induces a rapid redistribution of glycoprotein Ib-IX complexes within the membrane systems of activated human platelets. Blood 76:1503–1513
Stel HV, Sakariassen KS, Scholte BJ, Veerman EC, van der Kwast TH, de Groot PG, Sixma JJ, van Mourik JA (1984) Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 63:1408–1415
Swords NA, Mann KG (1993) The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb 13:1602–1612
Santoro SA (1986) Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 46:913–920
Kunicki TJ, Nugent DJ, Staats SJ, Orchekowski RP, Wayner EA, Carter WG (1988) The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem 263:4516–4519
Santoro SA, Rajpara SM, Staatz WD, Woods VL Jr (1988) Isolation and characterization of a platelet surface collagen binding complex related to VLA-2. Biochem Biophys Res Commun 153:217–223
Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H (1987) A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 69:1712–1720
Kehrel B, Kronenberg A, Rauterberg J, Niesing-Bresch D, Niehues U, Kardoeus J, Schwippert B, Tschope D, van de LJ, Clemetson KJ (1993) Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V Blood 82: 3364–3370
Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ (1985) Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 318:470–472
Kehrel B (2000) Platelet receptors for collagen. Platelets 6:11–16
Alberio L, Dale GL (1998) Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall. Br J Haematol 102:1212–1218
Brass LF (1991) The biochemistry of platelet activation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ (eds) Hematology: basic principles and practice. Churchill Livingston, New York, pp 1176–1197
Mammen EF, Barnhart MI, Silik NR et al (1988) “Sticky platelet syndrome” A congenital platelet abnormality predisposing to thrombosis. Folia Haematol 115:361–365
Bick RL (1998) Sticky platelet syndrome: a common cause of unexplained arterial and venous thrombosis. Clin Appl Thromb Hemost 4:77–81
Berg-Darner E, Henkes H, Trobrisch H, Kuhne D (1997) Sticky platelet syndrome: a cause of neurovascular thrombosis and thromboembolism. Intervent Neuroradiol 3:145–154
Chitter SR, Elschety AE, Roberts GF, Laughlin WR (1998) Sticky platelet syndrome: a case report and review of the literature. Clin Appl Thromb Hemost 4:280–284
Nurden AT, Caen JP (1975) Specific roles for platelet surface glycoproteins in platelet function. Nature 255:720–722
Nurden AT, Caen JP (1974) An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. Br J Haematol 28:253–260
Berndt MC, Gregory C, Chong BH, Zola H, Castaldi PA (1983) Additional glycoprotein defects in Bernard-Soulier’s syndrome: confirmation of genetic basis by parental analysis. Blood 62:800–807
Clemetson KJ, McGregor JL, James E, Dechavanne M, Luscher EF (1982) Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 70:304–311
Nurden AT, Didry D, Rosa JP (1983) Molecular defects of platelets in Bernard-Soulier syndrome. Blood Cells 9:333–358
Nurden AT (1999) Inherited abnormalities of platelets. Thromb Haemost 82:468–480
Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC (1998) Bernard-Soulier syndrome. Blood 91:4397–4418
Phillips DR, Jenkins CS, Luscher EF, Larrieu M (1975) Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature 257:599–600
Phillips DR, Agin PP (1977) Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 60:535–545
Nurden AT, Caen JP (1979) The different glycoprotein abnormalities in thrombasthenic and Bernard-Soulier platelets. Semin Hematol 16:234–250
Moroi M, Jung SM, Okuma M, Shinmyozu K (1989) A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84:1440–1445
Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K (1995) Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 89:124–130
Ryo R, Yoshida A, Sugano W, Yasunaga M, Nakayama K, Saigo K, Adachi M, Yamaguchi N, Okuma M (1992) Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen-induced platelet aggregation. Am J Hematol 39:25–31
Davey MG, Luscher EF (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 216: 857–858
Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC (1999) The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 82:357–364
Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR (1991) Domains specifying thrombin-receptor interaction. Nature 353:674–677
Vu TK, Hung DT, Wheaton VI, Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057–1068
Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tarn C, Coughlin SR (1998) A dual thrombin receptor system for platelet activation. Nature 394:690–694
Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC (1998) Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 95:6642–6646
Hou L, Howells GL, Kapas S, Macey MG (1998) The protease-activated receptors and their cellular expression and function in blood-related cells. Br J Haematol 101:1–9
Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF (1998) The human proteinase-activated re-ceptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 273:15061–15068
Bode AP, Sandberg H, Dombrose FA, Lentz BR (1985) Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 39:49–61
Sandberg H, Bode AP, Dombrose FA, Hoechli M, Lentz BR (1985) Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thromb Res 39:63–79
George JN, Lewis PC (1978) Studies on platelet plasma membranes. III. Membrane glycoprotein loss from circulating platelets in rabbits: inhibition by aspirin-dipyridamole and acceleration by thrombin. J Lab Clin Med 91:301–306
Blajchman MA, Senyi AF, Hirsh J, Genton E, George JN (1981) Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest 68:1289–1294
Khan I, Zucker-Franklin D, Karpatkin S (1975) Microthrombocytosis and platelet fragmentation associated with idiopathic/autoimmune thrombocytopenic purpura. Br J Haematol 31:449–460
Zucker-Franklin D, Karpatkin S (1977) Red-cell and platelet fragmentation in idiopathic autoimmune thrombocytopenic purpura. N Engl J Med 297:517–523
George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ (1986) Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 78:340–348
Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84: 3691–3699
Fox JE, Austin CD, Reynolds CC, Steffen PK (1991) Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 266:13289–13295
Wiedmer T, Shattil SJ, Cunningham M, Sims PJ (1990) Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 29:623–632
Miletich JP, Kane WH, Hofmann SL, Stanford N, Majerus PW (1979) Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood 54:1015–1022
Rosing J, Bevers EM, Comfurius P, Hemker HC, van Dieijen G, Weiss HJ, Zwaal RF (1985) Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood 65:1557–1561
Weiss HJ, Vicic WJ, Lages BA, Rogers J (1979) Isolated deficiency of platelet procoagulant activity. Am J Med 67:206–213
Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ (1989) Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 264:17049–17057
Bouchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB (1997) Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 272:9244–9251
Bouchard BA, Shatos MA, Tracy PB (1997) Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation. Arterioscler Thromb Vasc Biol 17:1–9
Altieri DC, Edgington TS (1989) Sequential receptor cascade for coagulation proteins on monocytes. Constitutive biosynthesis and functional prothrombinase activity of a membrane form of factor V/Va. J Biol Chem 264:2969–2972
Altieri DC, Edgington TS (1990) Identification of effector cell protease receptor-i. A leukocyte-distributed receptor for the serine protease factor Xa. J Immunol 145:246–253
Altieri DC, Stamnes SJ (1994) Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. Cell Immunol 155:372–383
Zaman GJ, Conway EM (2000) The elusive factor Xa receptor: failure to detect transcripts that correspond to the published sequence of EPR-i. Blood 96:145–148
Turitto VT, Weiss HJ, Baumgartner HR (1983) Decreased platelet adhesion on vessel segments in von Willebrand’s disease: a defect in initial platelet attachment. J Lab Clin Med 102:551–564
Stemerman MB, Baumgartner HR, Spaet TH (1971) The subendothelial microfibril and platelet adhesion. Lab Invest 24:179–186
Baumgartner HR, Muggli R, Tschopp TB, Turitto VT (1976) Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Haemost 35: 124–138
Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ (1988) The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 263: 16467–16470
Ahmad SS, Rawala-Sheikh R, Walsh PN (1989) Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem 264:3244–3251
Ahmad SS, Rawala-Sheikh R, Walsh PN (1989) Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 264:20012–20016
Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF (1985) The role of activated human platelets in prothrombin and factor X activation. Blood 65:319–332
Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ (1991) Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 266:17261–17268
Sinha D, Seaman FS, Koshy A, Knight LC, Walsh PN (1984) Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XL, J Clin Invest 73:1550–1556
Greengard JS, Heeb MJ, Ersdal E, Walsh PN, Griffin JH (1986) Binding of coagulation factor XI to washed human platelets. Biochemistry 25:3884–3890
Baglia FA, Walsh PN (1998) Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. Biochemistry 37:2271–2281
Sinha D, Koshy A, Seaman FS, Walsh PN (1985) Functional characterization of human blood coagulation factor XIa using hybridoma antibodies. J Biol Chem 260:10714–10719
Lipscomb MS, Walsh PN (1979) Human platelets and factor XL Localization in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XL, J Clin Invest 63:1006–1014
Walsh PN (1972) The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. Br J Haematol 22:393–405
Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJ (1986) Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77:405–415
Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE (1984) Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J Clin Invest 74:1221–1228
Janeway CM, Rivard GE, Tracy PB, Mann KG (1996) Factor V Quebec revisited. Blood 87:3571–3578
Lorand L, Konishi K (1964) Activation of the fibrin-stabilizing factor of plasma by thrombin. Arch Biochem Biophys 105:58
Booth NA (1994) The natural inhibitors of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds) Haemostasis and thrombosis. Churchill Livingstone, Edinburgh, pp 699–717
Brummel KE, Butenas S, Mann KG (1999) An integrated study of fibrinogen during blood coagulation. J Biol Chem 274:22862–22870
Mosesson MW (1997) Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinolysis 8:257–267
Blomback B (1996) Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 83:1–75
Kuijper PH, Gallardo Torres HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ (1997) Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 89:166–175
Weiss HJ, Baumgartner HR, Turitto VT (1987) Regulation of platelet-fibrin thrombi on subendothelium. Ann NY Acad Sci 516:380–397
Seydewitz HH, Witt I (1985) Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res 40:29–39
Southan C, Thompson E, Lane DA (1986) Direct analysis of plasma fibrinogen-derived fibrinopeptides by high-performance liquid chromatography. Thromb Res 43:195–204
Nossel HL, Yudelman I, Canfield RE, Butler VP Jr, Spanondis K, Wilner GD, Qureshi GD (1974) Measurement of fibrinopeptide A in human blood. J Clin Invest 54:43–53
Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T (1988) Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 82: 1700–1707
Eckhardt T, Nossel HL, Hurlet-Jensen A, La Gamma KS, Owen J, Auerbach M (1981) Measurement of desarginine fibrinopeptide B in human blood. J Clin Invest 67:809–816
Hantgan RR, Hermans J (1979) Assembly of fibrin. A light scattering study. J Biol Chem 254:11272–11281
Hantgan R, McDonagh J, Hermans J (1983) Fibrin assembly. Ann NY Acad Sci 408:344–366
Doolittle RF, Cassman KG, Chen R, Sharp JJ, Wooding GL (1972) Correlation of the mode of fibrin polymerization with the pattern of cross-linking. Ann N Y Acad Sci 202:114–126
McKee PA, Schwartz ML, Pizzo SV, Hill RL (1972) Cross-linking of fibrin by fibrin-stabilizing factor. Ann N Y Acad Sci 202:127–148
Gron B, Filion-Myklebust C, Bjornsen S, Haidaris P, Brosstad F (1993) Cross-linked alpha s gamma t-chain hybrids in plasma clots studied by 1D and 2D electrophoresis and Western blotting. Thromb Haemost 70:438–442
Gron B, Filion-Myklebust C, Bennick A, Nieuwenhuizen W, Matsueda GR, Brosstad F (1992) Early cross-linked fibrin in human plasma contains alpha-polymers with intact fibrinopeptide A. Blood Coagul Fibrinolysis 3:731–736
Lorand L, Chenoweth D, Domanik RA (1969) Chain pairs in the crosslinking of fibrin. Biochem Biophys Res Commun 37:219–224
Nuzzenzweig V, Seligmann M, Pelmont J, Grabar P (1961) Les produits de dégradation du fibrinogène humain par la plasmine. I. Séparation et propriétés physico-chimiques. Ann Inst Pasteur 100:377–388
Marder VJ, Shulman NR, Carroll WR (1969) High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physico-chemical and immunological characterization. J Biol Chem 244: 2111–2119
Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E (1999) D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 20:1493–1502
Wahlander K, Tengborn L, Hellstrom M, Olmarker AH, Peterson LE, Stigendal L, Larson G (1999) Comparison of various D-dimer tests for the diagnosis of deep venous thrombosis. Blood Coagul Fibrinolysis 10:121–126
Scarano L, Prandoni P, Gavasso S, Gomiero W, Carraro G, Girolami A (1999) Failure of soluble fibrin polymers in the diagnosis of clinically suspected deep venous thrombosis. Blood Coagul Fibrinolysis 10:245–250
Quinn DA, Fogel RB, Smith CD, Laposata M, Taylor TB, Johnson SM, Waltman AC, Hales CA (1999) D-dimers in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med 159:1445–1449
Markus G, Evers JL, Hobika GH (1978) Comparison of some properties of native (Glu) and modified (Lys) human plasminogen. J Biol Chem 253:733–739
Markus G, Priore RL, Wissler FC (1979) The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J Biol Chem 254:1211–1216
Olman MA, Hagood JS, Simmons WL, Fuller GM, Vinson C, White KE (1999) Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. Blood 94:2029–2038
Hajjar KA, Nachman RL (1988) Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest 82:1769–1778
Ellis V, Behrendt N, Dano K (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752–12758
Miles LA, Plow EF (1985) Binding and activation of plasminogen on the platelet surface. J Biol Chem 260:4303–4311
Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR, Masucci MT, Moller LB, Olson DP, Pedersen N, Ploug M (1990) The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 32:247–253
Vaheri A, Stephens RW, Salonen EM, Pollanen J, Tapiovaara H (1990) Plasminogen activation at the cell surface-matrix interface. Cell Differ Dev 32:255–262
Knudsen BS, Silverstein RL, Leung LL, Harpel PC, Nachman RL (1986) Binding of plasminogen to extracellular matrix. J Biol Chem 261:10765–10771
Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M (1990) Purification and characterization of a new arginine carboxy-peptidase in human serum. Biochim Biophys Acta 1034: 86–92
Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270:14477–14484
Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-depen-dent. Blood 88:2093–2100
Broze GJ Jr, Higuchi DA (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88:3815–3823
Bovill EG, Malhotra OP, Mann KG (1990) Mechanisms of vitamin K antagonism. In: Hirsh J (ed) Bailliere’s clinical haematology. Bailliere’s Publishing, pp 555–581
Mann KG and M Kalafataias (1995) The coagulation explosion. Cerebrovasc Dis 5:93–97
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Brummel, K.E., Jenny, N.S., Mann, K.G. (2002). Molecular and Cellular Hemostasis and Fibrinolysis. In: Lanzer, P., Topol, E.J. (eds) Pan Vascular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56225-9_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-56225-9_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62565-7
Online ISBN: 978-3-642-56225-9
eBook Packages: Springer Book Archive